When does palbociclib’s patent protection expire in Jordan?
The exact “patent expiration date in Jordan” depends on which specific Jordanian right is being enforced (for example, a product patent vs. a supplementary protection certificate) and on the patent family member filed in Jordan. Palbociclib (Ibrance) is protected in many countries through patents on the active ingredient and/or related inventions, but the legal end date in Jordan is not one universal date.
If you tell me the brand name you mean (typically Ibrance) and, if you have it, a Jordan patent number or the product/company name listed on Jordan’s patent register, I can help you pinpoint the applicable expiration.
How can I check the palbociclib patent expiry date in Jordan?
To get the correct expiration date for Jordan, you typically need to look up the specific patent record(s) in Jordan for palbociclib and then check the legal status and any term extensions. In practice, the workflow is:
1. Identify the relevant Jordan patent documents that cover palbociclib (active ingredient / composition / use).
2. Confirm the filing and grant details for those specific Jordan filings.
3. Check the status in the Jordan intellectual property registry (active, lapsed, or expired) and whether any extension mechanism applies.
Because each patent family can have multiple filings and term calculations, the “earliest expiry” can differ from the “effective protection” if there are multiple overlapping patents or exclusivity-like extensions.
Is Jordan’s palbociclib protection affected by supplementary protection certificates (SPCs)?
Some jurisdictions provide extra time for market authorization holders via mechanisms such as supplementary protection certificates. Whether Jordan offers an SPC system (and whether palbociclib received one) can change the effective end of exclusivity versus the base patent term. To determine this for palbociclib in Jordan, you must confirm whether an SPC (or any equivalent extension in Jordan) exists for the specific patent.
Could generic palbociclib be available before the last patent expires in Jordan?
Even before the last patent in a country expires, generics may enter depending on:
- Patent “early” expiry of one covering claim while other patents remain.
- Whether Jordan’s regulatory approval pathway allows listing or marketing while patent litigation is ongoing.
- Country-specific rules on patent linkage or regulatory exclusivity.
So the earliest “real-world availability” date may not match the final patent expiration date.
What evidence would best answer “expiration in Jordan” for your case?
To pin down a specific expiration date, the most useful details are:
- The exact Jordan patent number(s) (or a link/citation from the Jordan patent register).
- The patent holder listed in Jordan (often the innovator’s local/legal entity).
- Whether you’re asking about the active ingredient palbociclib or a specific formulation/use.
- Whether you care about “patent expiry” or “market exclusivity” in practice.
If you share any of those, I can narrow down the relevant protection and the likely expiry timing for Jordan.
Sources
I don’t have access to Jordan’s patent register or a provided document set in your message, so I can’t responsibly give a specific Jordan expiration date without risking inaccuracy.